Skip to main content
. 2019 Jul 5;11(7):948. doi: 10.3390/cancers11070948

Figure 1.

Figure 1

Stearoyl-CoA desaturase 1 (SCD1) as a molecular target for anticancer therapy. SCD1 inhibitors suppress cancer cell proliferation, tumor formation and growth, and cancer cell migration, invasion, metastasis, and stemness. SCD1 regulates these tumorigenic events indirectly through monounsaturated fatty acids (MUFA) synthesis or directly by modulating various signaling pathways (e.g., epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) mitogenic pathway, AKT/GSKβ/β-catenin pathway for stimulation of the epithelial–mesenchymal transition, and Wnt/β-catenin/Hippo pathway for the maintenance of cancer cell stemness). Red arrows indicate the anticancer effect of SCD1 inhibition.